These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21356265)

  • 1. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.
    Banu H; Renuka N; Vasanthakumar G
    Biochimie; 2011 Jun; 93(6):1028-36. PubMed ID: 21356265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.
    Sano E; Li W; Yuki H; Liu X; Furihata T; Kobayashi K; Chiba K; Neya S; Hoshino T
    J Comput Chem; 2010 Nov; 31(15):2746-58. PubMed ID: 20839301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study.
    Yao Y; Han WW; Zhou YH; Li ZS; Li Q; Chen XY; Zhong DF
    Eur J Med Chem; 2009 Feb; 44(2):854-61. PubMed ID: 18541345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).
    Davies C; Witham K; Scott JR; Pearson A; DeVoss JJ; Graham SE; Gillam EM
    Drug Metab Dispos; 2004 Apr; 32(4):431-6. PubMed ID: 15039296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
    Mosher CM; Hummel MA; Tracy TS; Rettie AE
    Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin.
    Seifert A; Tatzel S; Schmid RD; Pleiss J
    Proteins; 2006 Jul; 64(1):147-55. PubMed ID: 16639745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
    Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
    Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
    Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
    Dickmann LJ; Locuson CW; Jones JP; Rettie AE
    Mol Pharmacol; 2004 Apr; 65(4):842-50. PubMed ID: 15044613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.
    Shi R; Li J; Cao X; Zhu X; Lu X
    J Mol Model; 2011 Aug; 17(8):1941-51. PubMed ID: 21120554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
    Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
    Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical and experimental evaluation of a CYP106A2 low homology model and production of mutants with changed activity and selectivity of hydroxylation.
    Lisurek M; Simgen B; Antes I; Bernhardt R
    Chembiochem; 2008 Jun; 9(9):1439-49. PubMed ID: 18481342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the bound substrate in nitric oxide synthase protonated or neutral and what is the active oxidant that performs substrate hydroxylation?
    de Visser SP; Tan LS
    J Am Chem Soc; 2008 Oct; 130(39):12961-74. PubMed ID: 18774806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.
    Flanagan JU; McLaughlin LA; Paine MJ; Sutcliffe MJ; Roberts GC; Wolf CR
    Biochem J; 2003 Mar; 370(Pt 3):921-6. PubMed ID: 12482324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
    Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
    ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.
    Locuson CW; Gannett PM; Tracy TS
    Arch Biochem Biophys; 2006 May; 449(1-2):115-29. PubMed ID: 16545770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8.
    Jiang H; Zhong F; Sun L; Feng W; Huang ZX; Tan X
    Amino Acids; 2011 Apr; 40(4):1195-204. PubMed ID: 20848147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.